First diagnosed with ET and JAK2V617F was low alle burden. A year later no mutation, 2 years later still no JAK2V617F but acquired new TET2 mutation with unknown significance and mild fibrosis that was not there before. Im only on baby aspirin, nothing else.
Has anyone else had their JAK2V617F mutation dis... - MPN Voice
Has anyone else had their JAK2V617F mutation disappear completely and then have a TET2 of unknown significance come up? Only on aspirin?
Written by
TootsRoo
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Cut-off point for disease versus no disease for JAK2V617F mutation positive individuals
« …Furthermore, a novel observation was that no individuals with a myeloproliferative neoplasm were...
Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F
“Reports have demonstrated that the minuscule JAK2V617F clones with low VAF have a clinically...
Phylogenetic reconstruction of myeloproliferative neoplasm reveals very early origins and lifelong evolution
« The mean latency between JAK2V617F acquisition and clinical presentation was 31 years (range...
Update 7.1 - Very Good News
Very good news from the Quantitative Analysis regarding JAK2v617f Variant Allele Frequency....
Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
« Several lines of evidence suggest other factors contribute to the propensity to develop...
Introduction of myself, PMF, from China
The new INCB160058 targeting Jak2 V617f
New MF drugs in development by Incye
